Crossmark

Efficacy and safety of fruquintinib plus capecitabine as first-line treatment in patients with metastatic colorectal cancer ineligible for intravenous chemotherapy: a two-stage, single-armed, phase II study

Crossref DOI link: https://doi.org/10.1007/s10637-025-01510-1

Published Online: 2025-02-13

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Xin

Bai, Zhigang

Deng, Wei

Wang, Xinfeng
License Information

Text and Data Mining valid from 2025-02-13

Version of Record valid from 2025-02-13
More Information

Article History

Received: 24 December 2024

Accepted: 28 January 2025

First Online: 13 February 2025

Declarations

:

: The study procedures were approved by the Ethics Committee of Beijing Friendship Hospital and conducted in accordance with the Declaration of Helsinki and ethical guidelines.

: The clinical data of each patient were complete and true, and written informed consents were obtained from the patients and their children.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below